Prevent of death caused by E. coli k99 in infant mice by colicinogenic E. coli
Subject Areas : Medical Microbiology
Fatemeh
Golestan
1
(دانشگاه آزاد اسلامی، واحد جهرم، گروه میکروبیولوژی)
Yahya
Tahamtan
2
(گروه باکتری شناسی، موسسه تحقیقات واکسن و سرم سازی رازی، شیراز)
Masoumeh
Hayati
3
(گروه باکتری شناسی، موسسه تحقیقات واکسن و سرم سازی رازی، شیراز)
Elham
Moazamian
4
(دانشگاه آزاد اسلامی، واحد علوم و تحقیقات فارس، گروه میکروبیولوژی)
Keywords: E.coli K99, Colicinogenic Bacteria, Colicin,
Abstract :
Background and Objective: E. coli k99 is one of the major causes of diarrhea in neonatal calves. Colicin is an antimicrobial peptide produced by one strain of E. coli to suppress the growth of other strains of E. coli. The aim of this study was to control E. coli k99 infection in mice by oral administration of colicinogenic E. coli (CEC). Material and Methods: This experimental study was conducted on two groups of control and treatment infant mice, strain BALB/c. The control group was subdivided into two groups: one group was fed with colicinogenic E. coli (CEC) and the second control group was E. coli k99. The treatment group was administrated with colicinogenic E. coli (CEC) and also with E. coli k99 in intervals. Finally, the mortality rate of the mice was assayed in both treatment and control groups. Result: Results of this study delineated that all mice in the control group who were fed with colicinogenic E. coli was survived while 83% of the second control group (40 cases) died due to production of heat-stable enterotoxin. Our study showed that the mortality rate in the treatment group was significantly reduced, and the reduction rate was increased in higher doses of colicinogenic E. coli (CEC). Conclusion: Based on the antibacterial activity of CEC against E. coli k99, colicin is an appropriate choice for control of the infection. Furthermore, it is possible to replace colicins instead of conventional antibiotics for control of the intestinal disorder.
1. Orden JA, Ruiz JA, Cid D, Fuente R, Presence and enterotoxigenicity of F5 and F41 Escherichia coli isolated from diarrhoeic small ruminant in Spain. Small Ruminant Research. 2002; 44(2): 159-161.
2. Steinsland H, Valentiner Branth P, Gjessing HK, Aaby P, Molbak K, and Sommerfelt H, Protection from natural infections with enterotoxigenic Escherichia coli, longitudinal study. Lancet. 2003; 362(9380): 286–291.
3. McDermott PF, Zhao S, Wagner DD, Simjee S, Walker RD, and White DG. The food safety perspective of antibiotic resistance. Anim Biotechnol. 2002; 13(1): 71–84.
4. Cutler AS, Lonergan SM, Cornick N, Johnson AK, and Stahl CH. Dietary Inclusion of Colicin E1 Is Effective in Preventing Postweaning Diarrhea Caused by F18-Positive Escherichia coli in Pigs. Antimicrob agents Chemother. 2007; 51(11): 3830-3835.
5. Diez-Gonzalez F. Applications of bacteriocins in livestock. Curr Issues Intest Microbiol. 2007; 8(1): 15-23.
6. Cascales F, Buchanan S, Duche D, Kleanthous C, Lloubes R, Postle k, Riley M, Slatin S, and Cavaral D. Colicin Biology. Microbiol Mol Biol Rev. 2007; 71(1): 158-229.
7. Minelli EB, Benini A. Relationship between number of bacteria and their probiotic effects. Microb Ecol Health D. 2008; 20: 180-183.
8. Shirazi Z. Bacteriocin inhibitory effect against enterotoxigenic Escherichia coli K99 strain [dissertation].Department of Microbiology, Islamic Azad University, Jahrom Branch, Jahrom, Iran; 2011. [ In Persion]
9. Braude AI, Siemienski JS. The influence of bacteriocins on resistance to infection by Gram-negative bacteria. J Clin Invest. 1968; 47(8): 1763-1773.
10. Smith HW, Huggins MB. Treatemt Of experimental Eshericha coli infection in mice with colicin V. J Med Microbiol. 1977; 10(4): 479-482.
11. Schamberger GP, Diez-Gonzalez F. Characterization of colicinogenic Escherichia coli strains inhibitory to enterohemorrhagic E.coli. J Food Prot. 2004; 67(3): 486–492.
12. Gillor O, Giladi I, Riley MA. Persistence of colicinogenic Escherichia coli in the mouse gastrointestinal tract. BMC Microbiol. 2009; 9: 165-172.
